Canopy(1) | $22,000,000 | (Jan 13, 2026)
Onsetto | $2,200,000 | (Jan 13, 2026)
BlueNalu | $11,000,000 | (Jan 13, 2026)
Certified by Founder
Lodge
Delphia Therapeutics
start up
United States
- Cambridge, Massachusetts
- 07/05/2024
- Series A
- $67,000,000
Delphia Therapeutics is a biotechnology company pioneering activation lethality, a new area of cancer therapeutics that target cancer's surprising vulnerability to oncogene overactivation. Delphia’s activation lethality platform offers the potential for first-in-class targeted cancer medicines that are effective on their own while also combating the emergence of drug resistance to classic targeted therapies.
- Industry Biotechnology Research
- Website https://www.delphiatx.com/
- LinkedIn https://www.linkedin.com/company/delphia-therapeutics/
Cytotheryx, Inc. | $60,000,000 | (Jan 13, 2026)
MEDIPOST, Inc. | $140,000,000 | (Jan 13, 2026)
TRYBE | $30,000,000 | (Jan 13, 2026)
Kinaset Therapeutics | $103,000,000 | (Jan 13, 2026)
Diagonal Therapeutics | $125,000,000 | (Jan 13, 2026)
VelaFi | $20,000,000 | (Jan 13, 2026)
encoord | $2,000,000 | (Jan 13, 2026)
Avenue Biosciences | $7,500,000 | (Jan 13, 2026)
Unusual | $3,600,000 | (Jan 13, 2026)